CHEK2 and neoplasm: No significant associations were found with tumour stage or treatment.<h4>Conclusions</h4>In this Portuguese cohort, nearly 12% of consecutive real-world MGPT-tested gastric cancer patients had germline pathogenic or likely pathogenic variants, predominantly in mismatch repair genes but also in CHEK2 and BLM.